CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.